Starpharma Pty Limited

Verva Pharmaceuticals Ltd

Baker Idi Heart and Diabetes Institute Holdings Limited

Naia Metabolic, Inc.

Guy Yeoman Krippner

Brian Devlin Kelly

Pasquale Razzino

Benjamin James Boyd

Lisa Michelle Kaminskas

Christopher John Hamilton Porter

Zemin Wu

Scott Andrew Henderson

Nicky Konstantopoulos

Juan-Carlos Molero-Navajas

James Alexander Campbell

Kenneth Russell Walder

Gregory Royce Collier

Charlotte Claire Williams

Gottfried Lichti

Peter Karellas

Phillip Martin Rendle

Sue Pallich

Susanne Pallich

Angela Michelle Scheppokat

Ben William Greatrex

Christopher John Porter

Karlheinz Peter

David James Owen

Christoph Hagemeyer

The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitizers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present invention further relates to compounds and agents and compositions thereof for use in the treatment methods.

Insulin sensitisers and methods of treatment

The present invention relates generally to branched macromolecules and their use as imaging or contrast agents. In particular, the invention relates to dendrimers, derived from lysine or lysine analogs, bearing a plurality of functional moieties and their application to imaging techniques in which a disease state may be imaged with a targeted contrast agent.

Polylysine dendrimer contrast agent

The present invention relates to a macromolecule having a controlled terminal group stoichiometry, the macromolecule including a surface layer, at least one subsurface layer and at least two terminal groups including: a first terminal group which is a residue of a pharmaceutically active agent, a derivative thereof or precursor therefor; and a second terminal group selected to modify the pharmacokinetics of the pharmaceutically active agent and/or macromolecule, wherein terminal group stoichiometry refers to the number and type of terminal groups.

Modified macromolecule

The following invention is directed to macromolecules having controlled stoichiometry and topology, processes for their production, and applications for their use. The macromolecules have a controlled functional moiety stoichiometry and include at least one dendritic motif having a surface layer formed from at least one surface building unit and at least one subsurface layer formed from at least one building unit, the surface building unit and building units having a hydrocarbon backbone bearing a carbonyl group and at least one amine group; and at least two different functional moieties on the building unit and/or surface building unit; where functional moiety stoichiometry refers to the number and type of functional moieties.

Macromolecular compounds having controlled stoichiometry

The present invention relates generally to branched macromolecules bearing functional moieties. In particular, the invention relates to dendrimers, derived from lysine or lysine analogues, bearing a plurality of functional moieties. The invention further relates to the use of such macromolecules, particularly in therapeutic applications, and compositions comprising them.

Targeted polylysine dendrimer therapeutic agent

Growing community of inventors

Newtown, Australia

Guy Yeoman Krippner